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D ermatomyositis (DM) is an idiopathic inflam-matory myopathy characterized predominantly 
by cutaneous and muscular abnormalities.  DM patients 
who exhibit cutaneous manifestations of DM without 
muscle weakness for < 6 months and who experience 
fatal complications such as acute or subacute interstitial 
lung disease (ILD) are also diagnosed with clinically 
amyopathic dermatomyositis (CADM) according to 
Gerami’s criteria [1].  Pulmonary complications are the 
main cause of death in CADM,  and severe ILD and 
pneumomediastinum are potentially the most 
life-threatening complications.  Steroid monotherapy is 
insufficient for CADM,  and intensive immunosuppres-
sion therapy is usually needed.
Case Report
A 66-year-old Japanese woman developed skin 
eruptions on the eyelid and finger 3 months before pre-
sentation.  Additionally,  she experienced intense mus-
cle weakness and myalgia.  She also started to exhibit 
continuous high-grade fever ( > 38°C).  Her condition 
had been controlled with prednisolone 10 mg per day 
for a clinical diagnosis of polymyalgia rheumatica.  
Despite the low-dose steroid monotherapy for three 
months,  her condition as well as the proximal muscular 
weakness gradually worsened,  and she could not rise 
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We report a case of a woman with typical dermatomyositis (DM) with skin manifestations,  severe myalgia 
and muscle weakness complicated by interstitial lung disease (ILD) and pneumomediastinum.  
Pneumomediastinum persisted despite treatment with immunosuppressive therapy (steroids and cyclosporine).  
After the test for anti-melanoma differentiation-associated gene 5 (MDA5) antibody came out positive,  we dou-
bled the cyclosporine dose and her condition improved.  Despite typical clinical features of DM,  in cases com-
plicated by pneumomediastinum or steroid resistance,  measurement of anti-MDA5 antibody may be useful for 
immunosuppressant dose titration.  
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from a lying down position.  She was suspected as suf-
fering from another connective tissue disease and was 
referred to our department.  A physical examination on 
admission showed a severe heliotrope rash with impres-
sive eyelid edema,  2 small oral ulcerations,  and 
Gottron’s papules and Mechanics’ hands,  but did show 
not cuticle extension or nail fold bleeding.  She had not 
experienced Raynaud’s phenomenon.  Symmetrical 
proximal muscle weakness was apparent (Table 1).  
Results of laboratory tests on admission showed 
increased muscle and liver enzymes (Table 2).  In addi-
tion,  she had a bit of cough without hypoxia (SpO2 
98%); a chest radiograph revealed bilateral opacities,  
and computed tomography (CT) showed bilateral 
ground-glass opacity in the subpleural areas of consoli-
dation (Fig . 1).  The patient was diagnosed with DM 
complicated by ILD given her skin lesions,  muscle 
weakness and inflammation.  A muscle biopsy revealed 
type 2 fiber atrophy and various sizes of muscle fibers 
and slight lymphocytic infiltration around the muscle 
tissue but no perifascicular myofibers (Fig . 2).  We mea-
sured anti-ARS antibody on admission performed for 
patients suspected as having DM; however,  the result 
was negative.  The presence of malignancies was 
excluded.
High doses of steroids (45 mg; 1 mg/kg/day) and 
oral cyclosporine A (100 mg; 2 mg/kg/day) were used 
as initial therapy.  Several days later,  the heliotrope rash 
improved rapidly,  and the facial edema decreased as 
well but did not completely resolve.  Additionally,  the 
patient recovered from proximal muscle weakness.  Two 
weeks later,  the dose of steroids was decreased to 
30 mg,  and she was discharged from the hospital.  
Two weeks later,  she returned to the hospital with 
severe pain when swallowing.  The CT showed a newly 
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Table 2　 Summary of laboratory tests on admission
Parameter
White blood cell count 9,390 /mm3
Neutrophils 92.8 %
Lymphocytes 4.9 %
Monocytes 2.9 %
Eosinophils 0 %
Basophils 0 %
Red blood cell count 366×104 /mm3
Hemoglobin 10.9 g/dl
Mean corpuscular volume 89.3 ﬂ
Platelet 28.1×104 /mm3
Total protein 6.5 g/dl
Albumin 2.8 g/dl
Aspartate aminotransferase 53 IU/l
Alanine Aminotransferase 37 IU/l
Blood Urea Nitrogen 36 mg/dl
Creatinine 0.3 mg/dl
Creatine phosphokinase 328 IU/l
Aldolase 4.5 IU/l
Myoglobin 146 mg/dl
C-reactive protein 2.35 mg/dl
Sialylated carbohydrate antigen KL-6 808 U/ml
Glucose 288 mg/dl
Na 130 mEq/l
K 4.1 mEq/l
Cl 94 mEq/l
Ca 8.2 mg/dl
Ferritin 2,416.9 ng/ml
Fluorescent Antinuclear Antibody <40 times
Anti-Scl-70 antibody (－ )
Anti-aminoacyl tRNA synthetase antibody (－ )
Anti-Ribonucleoprotein antibody (－ )
Anti-SS-A/Ro antibody (－ )
Anti-SS-B/La antibody (－ )
Table 1　 Results of manual muscle test on admission
Muscle groups Right Left Axial
Axial muscles 
Neck ﬂexors X X 3
Proximal muscles
Deltoid  6  5 X
Biceps  8  9 X
Gluteus maximus  8  8 X
Gluteus medius  8  8 X
Quadriceps 10 10 X
Distal muscles
Wrist extensors 10 10 X
Ankle dorsiﬂexors 10 10 X
Fig.  1　 Interstitial lung disease at admission.
developed pneumomediastinum (Fig. 3A , B).  We 
recalled that CADM can be frequently complicated by 
ILD and pneumomediastinum; thus,  we tested for the 
anti-MDA5 antibody,  which is highly specific for 
CADM.  
Anticipating a positive result,  we decreased the dose 
of steroids to 20 mg and doubled the dose of cyclospo-
rine to 200 mg (4 mg/kg/day).  She recovered gradually 
from pneumomediastinum and other skin symptoms 
and was discharged three weeks later.  Before she was 
discharged,  we obtained a positive result for the anti-
MDA5 antibody.  After discharge,  we measured the 2-h 
post-dose blood concentration (C2) level of cyclospo-
rine (1,460.4 ng/dl).  The adequate dosage of CyA was 
judged by this concentration.
Discussion
DM is a rare autoimmune disease characterized by 
skin involvement and striated muscle inflammation,  
possibly involving the upper esophagus and causing 
damage to the internal organs.  Damaged organs are 
frequently marked by the presence of autoantibodies 
[2].  In DM,  the pattern of circulating myositis-specific 
autoantibodies can provide useful information for sys-
temic complications and disease prognosis [3].  
Although the presence of anti-aminoacyl tRNA synthe-
tase (anti-ARS) antibodies is associated with chronic 
ILD,  anti-MDA5 antibodies are associated with acute/
subacute ILD [4].  Additionally,  pneumomediastinum 
is a refractory complication and tends to occur in DM 
patients with anti-MDA5 antibodies; compared with 
DM patients without pneumomediastinum,  those with 
pneumomediastinum had significantly higher frequen-
cies of anti-MDA5 antibodies (90.9 vs 52.4%, p = 0.02) 
[5].  In the management of ILD,  it is reported that CyA 
therapy with a 2-h post-dose blood concentration (C2) 
>1,000 ng/ml is effective,  resulting in a 1-year survival 
rate of 89% [6].  
Much has been said in recent years about the rela-
tion between anti-MDA5 antibodies and muscle weak-
ness.  The lack of clinical evidence of muscle weakness is 
more highly prevalent in anti-MDA5-positive patients 
than -negative patients (76% vs 48%) [7].  Additionally,  
Shinji S et al.  showed that of 8 Japanese anti-MDA5- 
positive DM patients,  none had muscle weakness [8].  
Although our patient may have presented advanced 
muscle weakness,  the clinical characteristics of anti- 
MDA5-positive DM patients are inconsistent,  as the 
disease onset occurred only 3 months after her skin 
manifestations emerged.  Thus,  our case is a bit atypical.
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Fig.  2　 Result of muscle biopsy.
A
B
Fig.  3　 Pneumomediastinum at return to clinic.
Regarding the therapies for CADM based on 
anti-MDA5-positive results,  Galimberti et al.  reported 
in their retrospective cohort study that the majority of 
patients (64%) needed additional medications to control 
their CADM within 6 months of the diagnosis.  Of 
30 patients with follow-up > 2 years,  27 (90%) required 
steroid-sparing medications to control their CADM,  
confirming that CADM is a therapeutic challenge [3].  
In another study,  although 83% of CADM patients 
treated with triple drug combination therapy survived,  
one patient with corticosteroid monotherapy died from 
ILD.  Additionally,  of the patients initially treated with 
corticosteroids and cyclosporine,  33% died from ILD 
and 17% required additional administration of cyclo-
phosphamide later on in the treatment [9].  The prog-
nosis of CADM may depend on whether prompt and 
intensive treatment can be started.  Fortunately,  our 
patient recovered well.  However,  if she relapses,  we 
may need to add cyclophosphamide [10].
In conclusion,  in DM cases with typical clinical 
manifestations,  such as severe myalgia and muscle 
weakness,  that also show resistance to steroids,  coex-
isting ILD,  or pneumomediastinum,  anti-MDA5 auto-
antibodies should be measured for prompt initiation of 
intensive immunosuppressive therapies.
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